• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

ServiceNow stock: Armis deal seen more than tripling its market opportunity

by December 24, 2025
written by December 24, 2025

ServiceNow (NYSE: NOW) investors may be concerned with the company spending $7.75 billion on buying Armis, but its CEO remains confident the deal will prove positive in the long run.

According to Bill McDermott, the agreement strengthens NOW’s footprint in artificial intelligence (AI) enabled cybersecurity and could help “more than triple” its market opportunity over time.

This statement alone suggests a near 3% post-announcement decline on December 23rd may be an opportunity for long-term investors to initiate or expand their positions in ServiceNow shares.  

Bernstein dubs Armis deal bullish for ServiceNow stock

Speaking with CNBC this morning, McDermott said the Armis deal positions ServiceNow to create an “AI control tower” for enterprises – and a senior Bernstein analyst seems to agree.

In his research note, Peter Weed dubbed the transaction “positive” for NOW, even calling Armis a “natural adjacency” to its existing platform.

What he means is: the cybersecurity startup fits logically with ServiceNow’s strengths in workflow and IT services management.

On Tuesday, Weed maintained his “outperform” rating on NOW shares, with a $218 price objective on a split-adjusted basis, indicating potential upside of another 45% upside from current levels.

As is evident, he recommends long-term investors to capitalise on today’s weakness in ServiceNow.

NOW shares are undervalued heading into 2026

Bernstein sees ServiceNow shares as worth owning heading into 2026, also because they’re one of the “cheapest” currently in software names, even though the company is growing well with no signs of a near-term slowdown.

“NOW’s price to 3-year-out free cash flow vs. growth rate is below the most bearish AI-narrative impacted large-cap application software peers like Adobe … and reputation-maligned Salesforce.”

According to Peter Weed, recent deals (including Moveworks in March 2025) are “normal” – and in no way indicative of a company struggling to meet its growth targets organically.

Note that Bernstein has previously called ServiceNow “the next Microsoft” – signalling immense confidence in its long-term growth and ability to dominate the enterprise software market.

How Wall Street recommends playing ServiceNow Inc

From a technical perspective as well, the Armis-driven sell-off in NOW stock looks like a buying opportunity.

Its near-term (20-day) relative strength index (RSI) currently sits at a tad above 36 – indicating the downward momentum is near exhaustion now.

What’s also worth mentioning is that Bernstein isn’t the only Wall Street firm keeping constructive on ServiceNow heading into the new year.

Consensus rating on the NYSE-listed firm also currently sits at “strong buy,” as per Barchart, with the mean target of $227 signalling potential for a whopping 50% upside in 2026.  

All in all, with strong analyst support, resilient growth, and technical indicators favouring buyers, ServiceNow stock’s recent dip (following Armis announcement) appears temporary – positioning NOW for significant further upside next year.

The post ServiceNow stock: Armis deal seen more than tripling its market opportunity appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Europe bulletin: UK fiscal test, France budget crunch, Samsung’s driverless bet
next post
Record demand fuels Russian wheat exports in December as profit margins turn positive

related articles

Kospi Index targets 6k as Wyckoff Theory points...

February 23, 2026

IDFC First Bank shares slump after ₹590 crore...

February 23, 2026

Morning brief: Asia markets rise, Bitcoin drops below...

February 23, 2026

Trump unveils Tech Corps to drive US AI...

February 23, 2026

FTSE 100 Index soared to a record high...

February 23, 2026

Rolls-Royce share price targets 1,500p ahead of earnings...

February 23, 2026

Novo stock drops 15% as obesity drug falls...

February 23, 2026

S&P and Dow Jones futures fall as Trump...

February 23, 2026

Domino’s tops Q4 US sales estimates on value...

February 23, 2026

Citrini research: S&P 500 to drop 38% from...

February 23, 2026
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Why is Netflix considering going all-cash for WBD assets?

    January 15, 2026
  • Epstein file drop includes ‘untrue and sensationalist claims’ about Trump, DOJ says

    December 23, 2025
  • Jill Biden’s ‘work husband’ runs for cover as privilege protection crumbles

    June 26, 2025
  • Trump accepts second state visit to UK, reveals letter from King Charles

    February 27, 2025
  • LCX Crypto Is Falling 6.84% Today. What’s the Forecast?

    July 18, 2024

Popular Posts

  • 1

    District judges’ orders blocking Trump agenda face hearing in top Senate committee

    April 2, 2025
  • 2

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 3

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 4

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 5

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024

Categories

  • Economy (829)
  • Editor's Pick (8,032)
  • Investing (1,029)
  • Stock (979)

Latest Posts

  • Trump promises cheaper drugs under TrumpRx, but economists say the long-term costs may be hidden

    December 23, 2025
  • Israel-Hamas peace deal reached soon after Trump says it’s ‘very close’ in White House note pass with Rubio

    October 9, 2025
  • Tom Cotton demands FDA probe into illegal Chinese ingredients in US weight loss drugs

    February 13, 2026

Recent Posts

  • After repeated promises from Biden administration that a cease-fire is close, war in Middle East is escalating

    September 20, 2024
  • RFK Jr. tapped to lead Department of Health and Human Services

    November 14, 2024
  • DAVID MARCUS: In Harlem, excitement for Mamdani and a warning for Cuomo

    November 2, 2025

Editor’s Pick

  • FDA phasing out some animal testing in ‘win-win’ for ethics and public health: commissioner

    April 10, 2025
  • Greta Thunberg slammed for using image of starved Israeli hostage to show Palestinians suffering in Gaza

    October 8, 2025
  • NEWT GINGRICH: The simplest way to make American life affordable again

    November 17, 2025
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock